OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是评估arimoclomol在参加IIa期双盲研究（AALS-001）的ALS患者中治疗6个月的安全性和耐受性。 次要目的是评估arimoclomol对ALS患者ALS特异性功能评定量表（ALSFRS-R）和用力肺活量（FVC）的长期影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the safety and tolerability of arimoclomol over six months of treatment in patients with ALS who participated in the phase IIa double-blind study (AALS-001). The secondary objective is to evaluate the long-term effect of arimoclomol on the ALS-specific functional rating scale (ALSFRS-R) and forced vital capacity (FVC) in patients with ALS.